Back to results
US 2023/0406856 A1Published application
SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
AssigneeFochon Biosciences, Ltd.
InventorsHaohan TAN, Qihong LIU, Yunling WANG, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
Life of this patent
Estimating the term…
Abstract
Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
Claims19
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from C1-10 alkyl and C3-10 cycloalkyl, wherein the alkyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from RX;
- each R2 is independently selected from halogen and methyl;
- each RX is independently selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl, heteroaryl-C1-4 alkyl, halogen, CN, —NO2, —NRaRb, —ORa, —SRa, —S(O)rRa, —S(O)2ORa, —OS(O)2Rb, —S(O)rNRaRb, —P(O)RaRb, —P(O)(ORa)(ORb), —(CRcRd)NRaRb, —(CRcRd)tORb, —(CRcRd)tSRb, —(CRcRd)tS(O)rRb, —(CRcRd)tP(O)RaRb, —(CRcRd)tP(O)(ORa)(ORb), —(CRcRd)tCO2Rb, —(CRcRd)tC(O)NRaRb, —(CRcRd)tNRaC(O)Rb, —(CRcRd)tNRaCO2Rb, —(CRcRd)tOC(O)NRaRb, —(CRcRd)tNRaC(O)NRaRb, —(CRcRd)tNRaSO2NRaRb, —NRa(CRcRd)NRaRb, —O(CRcRd)tNRaRb, —S(CRcRd)tNRaRb, —S(O)r(CRcRd)tNRaRb, —C(O)Ra, —C(O)(CRcRd)tORb, —C(O)(CRcRd)tNRaRb, —C(O)(CRcRd)tSRb, —C(O)(CRcRd)tS(O)rRb, —CO2Rb, —CO2(CRcRd)tC(O)NRaRb, —OC(O)Ra, —C(O)NRaRb, —NRaC(O)Rb, —OC(O)NRaRb, —NRaC(O)ORb, —NRaC(O)NRaRb, —NRaS(O)rRb, —CRa(═N—ORb), —C(═NRe)Ra, —C(═NRe)NRaRb, —NRaC(═NRe)NRaRb, —CHF2, —CF3, —OCHF2 and —OCF3, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from OH, CN, amino, halogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
- each Ra and each Rb are independently selected from hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino, di(C1-10 alkyl)amino, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl and heteroaryl-C1-4 alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
- or Ra and Rb together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
- each Rc and each Rd are independently selected from hydrogen, halogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino, di(C1-10 alkyl)amino, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl and heteroaryl-C1-4 alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
- or Rc and Rd together with the carbon atom(s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
- each Re is independently selected from hydrogen, CN, NO2, C1-10 alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, —C(O)C1-4 alkyl, —C(O)C3-10 cycloalkyl, —C(O)OC1-4 alkyl, —C(O)OC3-10 cycloalkyl, —C(O)N(C1-4 alkyl)2, —C(O)N(C3-10 cycloalkyl)2, —S(O)2C1-4 alkyl, —S(O)2C3-10 cycloalkyl, —S(O)2N(C1-4 alkyl)2 and —S(O)2N(C3-10 cycloalkyl)2;
- m is selected from 0, 1, 2, 3, 4 and 5;
- each r is independently selected from 0, 1 and 2;
- each t is independently selected from 0, 1, 2, 3 and 4.
9 more elements
A compound selected from
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.